Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 20/20 | 0.71 |
| ▸ | JAK2 | O60674 | 8/20 | 0.70 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17820785 | 1.00 | NTRK1 (0.71) | NTRK1JAK2NTRK3 | |
| SCHEMBL2599300 | 0.90 | NTRK1 (0.60) | NTRK1JAK2 | |
| SCHEMBL2599251 | 0.90 | NTRK1 (0.60) | NTRK1JAK2 | |
| SCHEMBL17820911 | 0.87 | NTRK1 (0.69) | NTRK1JAK2 | |
| SCHEMBL17820881 | 0.87 | NTRK1 (0.69) | NTRK1JAK2 | |
| SCHEMBL17820913 | 0.87 | NTRK1 (0.69) | NTRK1JAK2 | |
| SCHEMBL17820883 | 0.87 | NTRK1 (0.69) | NTRK1JAK2 | |
| SCHEMBL2599218 | 0.86 | NTRK1 (0.64) | NTRK1JAK2NTRK3 | |
| SCHEMBL2599220 | 0.86 | NTRK1 (0.64) | NTRK1JAK2NTRK3 | |
| SCHEMBL23967315 | 0.85 | NTRK1 (0.74) | NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4420732-A2 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | CMG Pharmaceutical Co., Ltd. (KR) | 2024-08-28 | — | — | EP | disclosed |
| EP-3233863-B1 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | CMG PHARMACEUTICAL CO LTD (KR) | 2024-04-10 | — | — | EP | disclosed |
| WO-2021042890-A1 | HETEROCYCLIC COMPOUND AND APPLICATION THEREOF AS TRK KINASE INHIBITOR | 罗欣药业(上海)有限公司 | 2021-03-11 | — | — | WO | disclosed |
| EP-3233863-A1 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | CMG Pharmaceutical Co., Ltd. (KR) | 2017-10-25 | — | — | EP | disclosed |
| US-9701681-B2 | Fused ring heteroaryl compounds and their use as Trk inhibitors | CMG PHARMACEUTICAL CO., LTD. (KR) | 2017-07-11 | — | — | US | disclosed |
| US-9701681-B2 | Fused ring heteroaryl compounds and their use as Trk inhibitors | CMG PHARMACEUTICAL CO., LTD. (KR) | 2017-07-11 | — | — | US | disclosed |
| US-9701681-B2 | Fused ring heteroaryl compounds and their use as Trk inhibitors | CMG PHARMACEUTICAL CO., LTD. (KR) | 2017-07-11 | — | — | US | disclosed |
| WO-2016097869-A1 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | CMG PHARMACEUTICAL CO., LTD. (KR) | 2016-06-23 | — | — | WO | disclosed |
| US-20160168156-A1 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | HANDOK INC. (KR) | 2016-06-16 | — | — | US | disclosed |
| US-20160168156-A1 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | HANDOK INC. (KR) | 2016-06-16 | — | — | US | disclosed |
| US-20160168156-A1 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | HANDOK INC. (KR) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168156-A1 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | NR4A3, NR4A1, NR3C1 | NTRK1 5/4885JAK2 1535/4885NTRK3 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.